Kavar Capital Partners Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Kavar Capital Partners Group’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,500	Closed	-$1K	–	503
2019 Q2	$1K	Buy	+4,500	New	+$911	﹤0.01%	500
2018 Q3	–	Sell	-1,500	Closed	-$2K	–	437
2018 Q2	$2K	Hold	1,500	–	–	﹤0.01%	420
2018 Q1	$3K	Buy	+1,500	New	+$2.82K	﹤0.01%	398
2016 Q1	–	Sell	-1,500	Closed	-$9K	–	457
2015 Q4	$9K	Hold	1,500	–	–	0.01%	276
2015 Q3	$11K	Hold	1,500	–	–	0.01%	278
2015 Q2	$9K	Buy	+1,500	New	+$11.6K	0.01%	307
2014 Q2	–	Sell	-2,000	Closed	-$13K	–	487
2014 Q1	$13K	Hold	2,000	–	–	0.01%	297
2013 Q4	$11K	Buy	+2,000	New	+$13.1K	0.01%	293

Other funds holding GNMX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kavar Capital Partners Group's GNMX Position: Q3 2019 in Review

Kavar Capital Partners Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2019, closing a stake of 4,500 shares — an estimated $1K sold.

Kavar Capital Partners Group first reported a position in GNMX in Q4 2013 and held it in 8 quarters. The position peaked at $13K in Q1 2014. 25 funds tracked by Wall St. Rank hold GNMX as of Q3 2019.

Kavar Capital Partners Group reported no remaining Aevi Genomic Medicine Inc position as of Q3 2019 after selling out during the quarter.
Kavar Capital Partners Group sold 4,500 Aevi Genomic Medicine Inc shares in Q3 2019, an estimated $1K.
Kavar Capital Partners Group first reported a position in Aevi Genomic Medicine Inc in Q4 2013 and held it in 8 quarters.
Kavar Capital Partners Group's Aevi Genomic Medicine Inc position peaked at $13K in Q1 2014.
25 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2019.

Based on Kavar Capital Partners Group's 13F filing for Q3 2019, filed 12 Nov 2019.